- Home
- VIGL vs OPTN Comparison
VIGL vs OPTN Comparison
Compare VIGL & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- OPTN
- Stock Information
- Founded
- VIGL 2020
- OPTN 2010
- Country
- VIGL United States
- OPTN United States
- Employees
- VIGL N/A
- OPTN N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- OPTN Health Care
- Exchange
- VIGL Nasdaq
- OPTN Nasdaq
- Market Cap
- VIGL 95.2M
- OPTN 78.4M
- IPO Year
- VIGL 2022
- OPTN 2017
- Fundamental
- Price
- VIGL $1.70
- OPTN $0.42
- Analyst Decision
- VIGL Buy
- OPTN Strong Buy
- Analyst Count
- VIGL 6
- OPTN 3
- Target Price
- VIGL $16.60
- OPTN $3.00
- AVG Volume (30 Days)
- VIGL 387.1K
- OPTN 924.6K
- Earning Date
- VIGL 11-07-2024
- OPTN 11-12-2024
- Dividend Yield
- VIGL N/A
- OPTN N/A
- EPS Growth
- VIGL N/A
- OPTN N/A
- EPS
- VIGL N/A
- OPTN N/A
- Revenue
- VIGL N/A
- OPTN $75,672,000.00
- Revenue This Year
- VIGL N/A
- OPTN $13.42
- Revenue Next Year
- VIGL N/A
- OPTN $52.99
- P/E Ratio
- VIGL N/A
- OPTN N/A
- Revenue Growth
- VIGL N/A
- OPTN 5.13
- 52 Week Low
- VIGL $1.60
- OPTN $0.32
- 52 Week High
- VIGL $6.06
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- VIGL 23.30
- OPTN 35.42
- Support Level
- VIGL $1.60
- OPTN $0.39
- Resistance Level
- VIGL $2.46
- OPTN $0.57
- Average True Range (ATR)
- VIGL 0.16
- OPTN 0.05
- MACD
- VIGL -0.02
- OPTN -0.00
- Stochastic Oscillator
- VIGL 11.63
- OPTN 16.53
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.